# Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma

> **NCT06585527** · PHASE1 · RECRUITING · sponsor: **Beijing Neurosurgical Institute** · enrollment: 30 (estimated)

## Conditions studied

- Glioblastoma Multiforme
- Glioma, Malignant

## Interventions

- **BIOLOGICAL:** TS-2021

## Key facts

- **NCT ID:** NCT06585527
- **Lead sponsor:** Beijing Neurosurgical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-29
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06585527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06585527, "Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06585527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*